
    
      NH004 contains the anticholinergic agent tropicamide and is delivered in a convenient product
      form (intra-oral dissolvable thin films) designed for the management of sialorrhea. This
      study is a double blind, placebo-controlled, crossover study of the safety and potential
      efficacy of three doses of of NH004 films for the short-term relief of the symptoms of
      sialorrhea in Parkinson's disease patients.

      A total of up to 36 Parkinson's disease patients will be enrolled in the study in two Phases.
      Phase A will include 12 patients and Phase B up to 24 patients. There will be an interim
      analysis after conclusion of Phase A. In both phases patients will be randomized into one of
      four groups. Each group will have a distinctive sequence for receiving intra-oral dissolvable
      films of 0.3 mg, 1 mg, 3 mg of NH004, or placebo during four visits.
    
  